loading page

Efficacy of PARPi monotherapy and the impact to subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse
  • +8
  • Kun Song,
  • Yana Ma,
  • Ning Li,
  • Hualei Bu,
  • Yongwen Huang,
  • Chengjuan Jin,
  • Hao Wen,
  • Shuai Feng,
  • Hui Zhang,
  • Beihua Kong,
  • Lingying Wu
Kun Song
Shandong University Qilu Hospital

Corresponding Author:songkun2001226@sdu.edu.cn

Author Profile
Yana Ma
Qilu Hospital of Shandong University
Author Profile
Ning Li
Chinese Academy of Medical Sciences & Peking Union Medical College
Author Profile
Hualei Bu
Shandong University Qilu Hospital
Author Profile
Yongwen Huang
Sun Yat-sen University Cancer Center
Author Profile
Chengjuan Jin
Shanghai General Hospital
Author Profile
Hao Wen
Fudan University Shanghai Cancer Center
Author Profile
Shuai Feng
Shandong Cancer Hospital and Institute
Author Profile
Hui Zhang
The Fourth Affiliated Hospital of Hebei Medical University
Author Profile
Beihua Kong
Shandong University Qilu Hospital
Author Profile
Lingying Wu
Chinese Academy of Medical Sciences & Peking Union Medical College
Author Profile

Abstract

Objective: The therapeutic effect of PARP inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive. Design: Retrospective cohort study. Setting: Patients from seven medical centers in China. Population: BRCA1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse, without any maintenance regimen after first- and second-line platinum therapy, and the secondary platinum-free interval (PFI) was more than 6 months. Methods: Patients in study group (n=31) were treated with PARPi monotherapy until disease progression, and patients in control group (n=33) were treated with platinum-based chemotherapy without restriction. Main Outcome Measures: RECIST and GCIG standard, Kaplan-Meier plotter Results: The objective response rate (ORR: 77.4% vs. 84.0%, p=0.538) and median progression-free survival (mPFS: 8.6 vs. 11.1 months, p=0.679) were comparable. PARPi monotherapy significantly prolonged post-recurrent survival (PRS, HR=0.35, p=0.024), and was the independent factor associated with PRS (HR=0.33, p=0.038). The median time from treatment to first subsequent therapy or death (TFST) of patients with platinum-based chemotherapy after PARPi progression and patients in control group with PFI≥6months after third-line platinum-based chemotherapy was comparable (mTFST: 7.5 vs. 7.1 months, p=0.800). Further survival analysis showed that PRS of patients with PARPi monotherapy were similar to patients with PFI≥6 months after third-line platinum chemotherapy (HR=0.66, p=0.503), and superior to patients with PFI<6 months after third-line platinum chemotherapy (HR=0.15, p=0.009). Conclusions: PARPi monotherapy was equivalent to platinum-based chemotherapy for BRCA1/2-mutated ovarian cancer patients with secondary platinum-sensitive recurrence, and could improve prognosis.